- Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-oncogene 1 ( ROS1), and ret proto-oncogene ( RET) gene rearrangements can benefit from specific kinase inhibitors. Detection of fusion genes is critical for determining the best treatment. Assessing rearrangements in non-small cell lung cancer remains challenging, particularly for lung cytology
BACKGROUND: EML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cance...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
INTRODUCTION:The report of cases of lung squamous cell cancers harboring anaplastic lymphoma kinase ...
- Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-...
Gene fusions are frequent chromosomal aberrations in solid tumors. In Lung cancer (LC) several drugg...
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are re...
Non Small Cell Lung Cancer (NSCLC) represents the most leading cause of death for cancer worldwide.1...
BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyros...
Abstract Background Complex kinase rearrangement, a mutational process involving one or two chromoso...
Precision medicine requires accurate multi-gene clinical diagnostics. We describe the implementation...
The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cance...
Approximately 7% of non-small cell lung carcinomas (NSCLCs) harbor oncogenic fusions involving ALK, ...
Accurate histological classification and identification of fusion genes represent two cornerstones o...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
Data de publicació electrònica: 19-04-2021The effectiveness of targeted therapies with tyrosine kina...
BACKGROUND: EML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cance...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
INTRODUCTION:The report of cases of lung squamous cell cancers harboring anaplastic lymphoma kinase ...
- Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-...
Gene fusions are frequent chromosomal aberrations in solid tumors. In Lung cancer (LC) several drugg...
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are re...
Non Small Cell Lung Cancer (NSCLC) represents the most leading cause of death for cancer worldwide.1...
BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyros...
Abstract Background Complex kinase rearrangement, a mutational process involving one or two chromoso...
Precision medicine requires accurate multi-gene clinical diagnostics. We describe the implementation...
The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cance...
Approximately 7% of non-small cell lung carcinomas (NSCLCs) harbor oncogenic fusions involving ALK, ...
Accurate histological classification and identification of fusion genes represent two cornerstones o...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
Data de publicació electrònica: 19-04-2021The effectiveness of targeted therapies with tyrosine kina...
BACKGROUND: EML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cance...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
INTRODUCTION:The report of cases of lung squamous cell cancers harboring anaplastic lymphoma kinase ...